Actively Recruiting
Deciphering How Food Intake Affects Sleepiness and Nighttime Sleep Quality in People With Type 1 Narcolepsy and Idiopathic Hypersomnia
Led by Hospices Civils de Lyon · Updated on 2024-11-12
60
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how food intake, sleepiness, and nighttime sleep quality interact in people with Type 1 Narcolepsy (NT1), Idiopathic Hypersomnia (IH), and healthy individuals. The study aims to better understand why obesity occurs frequently in NT1 patients and rarely in IH patients, focusing on how diet, body composition, and sleep patterns affect sleepiness and weight. The research explores whether eating high glycemic index foods increases sleepiness and how this might contribute to obesity in NT1 compared to IH and healthy controls. Participants will be monitored over several days using different devices and methods. Eating behaviors will be tracked through photos of meals taken with smartphones and a glucose sensor worn on the arm to monitor sugar intake. Sleep and wake patterns will be recorded using a sleep diary and an actigraphy device. Nighttime sleep quality and brain activity related to sleepiness will be measured with a portable sleep device called SOMFIT. Sleepiness will be assessed using a sleepiness scale at meal times and EEG markers recorded by the SOMFIT device. During the study, participants will provide data on their body mass index, body composition, and complete questionnaires about sleep quality, mood, and eating habits. The study will measure how glycemic load impacts sleepiness after lunch over three days. Researchers will analyze all these factors to understand the links between eating habits, sleepiness, and obesity. The overall study duration includes 4 to 5 days of at-home monitoring and assessments to gather comprehensive information.
CONDITIONS
Official Title
Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Type 1 Narcolepsy or Idiopathic Hypersomnia diagnosed by ICSD-3-TR or healthy controls without sleep disorder
- Familiar use of a smartphone
You will not qualify if you...
- Untreated moderate or severe sleep apnea syndrome
- Cognitive disorders incompatible with the study
- Unstable treatment or treatment with sodium oxybate
- Unstable medical or psychiatric conditions
- Shift work
- Pregnancy or breastfeeding
- Diabetes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Unité de Neurophysiologie-sommeil, Département de Neurologie, CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000
Not Yet Recruiting
2
Center for Sleep Medicine, Hospices Civils de Lyon
Lyon, France, 69004
Actively Recruiting
Research Team
L
Laure PETER-DEREX, MD-PhD
S
Solène PANTEL
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here